**Project Portfolio**

**Company Name**

City, State

Company logo

**Legal identification of the company (ies):**

**Project period:**

MM.YYYY – MM.YYYY

**Workstream(s):**

**Work package(s):**

Table of Content

[1 Project Outline 4](#_Toc92881373)

[1.1 Company Presentation 4](#_Toc92881374)

[1.2 Objectives of the company in the IPCEI in all technical fields it’s involved 4](#_Toc92881375)

[1.3 R&D Projects Before IPCEI 4](#_Toc92881376)

[1.4 Technology and Challenges – R&D&I Activities within IPCEI in all technical fields it’s involved 4](#_Toc92881377)

[1.5 First Industrial Deployment (FID) 4](#_Toc92881378)

[1.6 Intellectual Property Rights 4](#_Toc92881379)

[1.7 Work Plan 5](#_Toc92881380)

[1.8 Investment 6](#_Toc92881381)

[1.8.1 Tools and Equipment 6](#_Toc92881382)

[1.8.2 Construction of Buildings/Laboratory 6](#_Toc92881383)

[2 Budget 7](#_Toc92881384)

[2.1 Eligible Costs 7](#_Toc92881385)

[2.2 State Aid 7](#_Toc92881386)

[3 Integration of the project in the IPCEI Health 8](#_Toc92881387)

[4 Spill-over Effects 9](#_Toc92881388)

[4.1 Spill-over by non-protected results diffusion 9](#_Toc92881389)

[4.2 Spill-over by IP protected results diffusion 9](#_Toc92881390)

[4.3 Spill-over in FID phases 9](#_Toc92881391)

[*4.4* *Spill-over through collaboration with indirectly involved participants* 9](#_Toc92881392)

[5 Other positive effect on the market 10](#_Toc92881393)

[5.1 Increasing the level of R&D and innovations in Europe 10](#_Toc92881394)

[5.2 Impact of the Project on Employment and New Investments in Europe 10](#_Toc92881395)

[5.3 Environmental protection and energy dependence 10](#_Toc92881396)

[5.4 Coordination problems 10](#_Toc92881397)

[5.5 Imperfect and asymmetric information 10](#_Toc92881398)

[5.6 Adequacy of the state aid instrument 10](#_Toc92881399)

[6 Necessity and Proportionality 11](#_Toc92881400)

[6.1 Absence of similar projects 11](#_Toc92881401)

[6.2 Counterfactual scenario 11](#_Toc92881402)

[7 Elaboration on Terms of the Funding Gap Questionnaire 13](#_Toc92881403)

[7.1 Incentive effect 14](#_Toc92881404)

[7.1.1 Start date of the project 14](#_Toc92881405)

[7.1.2 Increase in R&D and FID efforts 14](#_Toc92881406)

[7.1.3 Risks affecting the project 14](#_Toc92881407)

[7.2 Necessity of state aid 14](#_Toc92881408)

[7.3 Proportionality of state aid 14](#_Toc92881409)

[7.3.1 Costs and state aid 14](#_Toc92881410)

[7.3.2 State aid cumulation 14](#_Toc92881411)

[7.3.3 Open selection proceeding 14](#_Toc92881412)

[8 Limitation of distortion of competition and trade 15](#_Toc92881413)

[8.1 Market affected by the state aid 15](#_Toc92881414)

[8.1.1 Current Industry Sector 15](#_Toc92881415)

[8.1.2 Market Situation / Share after IPCEI 15](#_Toc92881416)

[8.2 Limiting distortion of dynamic incentives 15](#_Toc92881417)

[8.3 No strengthening or creation of market power 15](#_Toc92881418)

[8.4 Failure to maintain an inefficient market structure 15](#_Toc92881419)

[8.5 No effect on location activities 15](#_Toc92881420)

[9 Annex to the Portfolio 16](#_Toc92881421)

1. Project Outline
	1. Company Presentation

*Please give a brief description of your company and type of company*

* 1. Objectives of the company in the IPCEI in all technical fields it’s involved

*Please give a brief description of the overall objectives of activities in all technical fields you’re involved, linking objectives between technical field.*

* 1. R&D Projects Before IPCEI

*Description of the R&D-parts which were necessary for the IPCEI project and that were carried out before start of the project (background).*

* 1. Technology and Challenges – R&D&I Activities within IPCEI in all technical fields it’s involved

*For each WP describe the state of art, the technical locks, the objective and the technical challenge to solve de technical locks.*

* 1. First Industrial Deployment (FID)

*For each WP describe the FID investment and linked Opex insisting on the description of beginning of FID (after R&D phases) and the end of FID (before mass production).*

*Cf. FID definition in Guidelines.*

* 1. Intellectual Property Rights

*IP management principles*

*IP protections principles*

*IP exploitation principles*

* 1. Work Plan

*Please describe your work plan in respect to the described work in the Chapeau document*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Workstream (WS)** | **No. of WP** | **Title** | **Person Months (PM)** | **PM(R&D&I)** |
|  |  |  |  |  |
|  |   |  |  |  |
|  |  |  |  |  |
|  |  | Total PM |  |  |

Table 1: Work Packages (WP) vs. Person Months (PM)

* 1. Investment
		1. Tools and Equipment

*Please cluster your investment by technology classification. Please provide also a brief and simple description of 1 or 2 sentences to the table (what is the purpose of the investment…).*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Technology** **Classification** | **No. of Tools**  | **Examplesof Tools** | **Investment Cost [EUR]** | **Year\***  | **WS** | **WP** |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  | Total |  |  |  |  |

\*investment year

Table 2: Overview of investment in tools and equipment

* + 1. Construction of Buildings/Laboratory

*Please provide a brief and simple description of 1 or 2 sentences to the table (what kind of building? for what purpose…). Please cluster your investment so that the table does not exceed 1 page.*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Technology** **Classification** | **No. of Tools**  | **Examplesof Tools** | **Investment Cost [EUR]** | **Year\***  | **WS** | **WP** |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  | Total |  |  |  |  |

\*investment year

Table 3: Overview of investment in buildings or laboratories

1. Budget
	1. Eligible Costs

Eligible costs only cover costs made for the purpose and the time span of the IPCEI:

• The following costs should be listed in a disaggregate manner:

• Costs for each of the R&D activities

• Costs for each of the FID activities

• And, within the FID costs, the costs of R&D carried out in the FID phase should be mentioned; this could give an idea of the overall importance of the R&D

• The cut-off date of the R&D and FID phases should be provided explicitly by each company (The template Excel contains vertical lines, showing these cut-offs, these should be adapted per company)

• Eligible costs cover costs up to the end of the FID phase (even if the FID phase goes beyond the national granting period for some companies)

• The end result of this step should be one figure: the total amount of eligible costs at the end of the IPCEI, including the FID phase

Note: all costs mentioned in the Excel sheet are considered by the Member States as eligible costs under the IPCEI Communication.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Construction of buildings/ laboratory etc.\* | Investment Costs\* | Personnel Costs | Subcontract Costs | Materials, Supplies and Others | Total Costs |
| RD |  |  |  |  |  |  |
| FID |  |  |  |  |  |  |

Table 4: Eligible Costs (R&D&I and First Industrial Deployment)[[1]](#footnote-1) [EUR]

\*: with respect of the terminal values at the end of first industrial deployment phase in MM.YYYY.

* 1. State Aid

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Technical Fields | Construction of buildings/ laboratory etc. | Investments | Personnel | Subcontracts  | Materials, Supplies and Others | State aid instrument | Planned Total State Aid | Gross grant equivalent |
| RDI |  |  |  |  |  |  |  |  |
| FID |  |  |  |  |  |  |  |  |

Table 5: State Aid (R&D&I and First Industrial Deployment) 1 [EUR]

1. Integration of the project in the IPCEI Health

*Please describe how your project concretely contributes to and significantly adds value for the achievement of the goals of each workstream (WS) to which you are participating and thus – to the achievement of the European objective pursued by the IPCEI.*

*Please describe how your project is complementary to the other individual projects in the IPCEI, thus contributing to the same objectives. Please address the following topics:*

* *Interlinkage of your project with other individual projects of the same workstream and across workstreams*
* *Your contribution to the overall IPCEI HEALTH objectives (of the WS objectives)*
* *List of important IPCEI-specific effective collaborations*
* *These collaboration should be*
	+ *1.) IPCEI-induced or IPCEI–enhanced,*
	+ *2.) related to the scope and the objectives of the IPCEI,*
	+ *3.) for individual R&D and FID projects (integrated into an IPCEI based on p.22-24 of the 2021 IPCEI Communication): “effective collaborations”.*
	+ *Their subject cannot be contractual research (performance of a research service or sub-contracting), neither simple supply/delivery relationships*
* *Evidence for the existence, the subject and the scope of such collaborations, as well as for the tasks of the collaboration partners must be provided (Letter of Intent, Memorandum of Understanding or some other appropriate document).*
* *In case the negotiations between the collaboration partners have not reached signing of binding collaboration agreement, please point out when the signature of the final binding collaboration agreement will be effected.*
* *In case of inability to provide a binding agreement at the stage of formal notification, please describe alternative means of effective delivery of the subject of the collaboration and its de-facto performance.*
1. Spill-over Effects
	1. Spill-over by non-protected results diffusion

*Publications and communication on IPCEI results*

* 1. Spill-over by IP protected results diffusion

*Please give information on the planned diffusion of IP protected results in a concrete and identifiable manner. For example the kind of licences (rec. Non exclusives FRAND), estimated no. of patents)*

* 1. Spill-over in FID phases

*Open infrastructures for SMES, RTO, start-up.*

* 1. *Spill-over through collaboration with indirectly involved participants*

*Please describe who are / who you consider to be your indirectly involved partners in general and how/why they were selected.*

*For each collaboration with an indirect partner, please describe in concrete terms and with sufficient details:*

1. *Who is the collaborating partner, its type (SME, large undertaking, research organisation)*
2. *What is the subject of this collaboration (IPCEI-related, induced or enhanced), how it relates to the IPCEI individual project of the IPCEI aid beneficiary*
3. *What are tasks and works to be performed, and contributions of each collaborating partner*

*Please provide evidence for the existence of such collaborations, as requested in the Chapter 3 (LOI, Memorandum of Understanding or some other appropriate document)*

*Please note, the collaboration relations to the indirect partners, included in this section, for individual R&D and FID projects (integrated into an IPCEI based on p.22-24 of the 2021 IPCEI Communication), must be “effective collaboration” and cannot be contractual research (performance of a research service or sub-contracting), neither simple supply/delivery relationship.*

*Please note that you do not need to duplicate the collaborations listed in this sub-section as spillovers in the other spillovers sub-sections. Instead, please chose, according to your views on the main area of importance or contribution, in which particular spillovers sub-section such a collaboration (especially with research organisations), should be included.*

1. Other positive effect on the market
	1. Increasing the level of R&D and innovations in Europe

*Description of how the project will increase the level of innovation and R&D in the sector and the European economy and society.*

* 1. Impact of the Project on Employment and New Investments in Europe

*Estimation of the quantitative and qualitative impact of your project on direct and indirect employment and training in European economy and society new investments in Europe.*

* 1. Environmental protection and energy dependence

*Description of the project influence on environment protection and on the reduction of energy dependence.*

*Description of planned positive effects on the life cycle assessment and, if possible, substantiated with key figures/target numbers, such as savings in tons of CO2 equivalents.*

* 1. Coordination problems

*Due to scale and complexity of the IPCEI explain the difficulty to work together particularly with:*

* *RTOs (not the same objective)*
* *SMEs, suppliers and customers (it’s easier to work in customer-supplier logic than in a cooperative)*
* *Competitors and sectors actors*

*Explain the difficulty due to the necessity to coordinate such a project with such divergent interests.*

* 1. Imperfect and asymmetric information

*Explain the risks of the project*

*Explain the difficulty to access to market finance*

*Explain the difficulty to recruit*

* 1. Adequacy of the state aid instrument

*Explain whether the state aid instrument is in adequacy to correct the market failure:*

* *Grant = coordination default and spill over*
* *Financial instrument = Imperfect and asymmetric information*
* *Recoverable advance = risks taken in the project prior to marketing*
1. Necessity and Proportionality
	1. Absence of similar projects

*Explain that there is no similar project in Europe*

* 1. Counterfactual scenario

*Describe explicitly the effect of the state aid incentive effect on your company.*

*Describe what will happen when funding will not be realized for the project. If you would not realize the project, how will your company maintain business capacity?*

*There should also be a counterfactual scenario at the overall IPCEI level, in order to understand what happens if the IPCEI would not take place. A counterfactual at IPCEI level could consist in technology developments taking place slower than with the aided IPCEI.*

*Description & substantiation of the counterfactual scenario at company level:*

*• The counterfactual scenario should be described in sufficient detail. E.g. a mere statement that “the company would not undertake the project as planned in its Member State without the aid” is not sufficient. It should be described in detail if it will not undertake the project at all, or will undertake it but in a different manner/extent, or will possibly undertake it somewhere else. As the IPCEI Communication requires, the intended change must be specified (the change in behaviour which is expected to result from the State aid, that is to say whether a new project is triggered, or the size, scope or speed of a project is enhanced; The change of behaviour has to be identified by comparing what would be the expected outcome and level of intended activity with and without aid).*

*• This description can be in the technological field documents, or, if confidential in nature, in the accompanying company level text document.*

*• It is vital to have sufficient substantiation of the counterfactual,* eg.via *authentic internal company documents, showing that the company faces a clear choice and how the decision on whether to carry out the project is taken. This requirement is in line with the documentary evidence required in RDI State aid cases.*

*Excel sheet calculations:*

*a) In the absence of alternative project:*

*• If the counterfactual scenario is that there is no alternative project, there is no need for a counterfactual project tab with calculations in the Excel sheet. The Commission will only assess the eligible cost and funding gap calculations for the basic scenario.*

*• Proportionality of aid amount per beneficiary company: two step check of the IPCEI Communication in case there is no alternative project:*

*1) Identify the eligible costs: The possible eligible costs are listed in the Annex of the IPCEI Communication. The aid amount for any beneficiary can in no case exceed 100% of the eligible costs;*

*2) Identify the funding gap.*

*In general, the aid amount corresponds to the funding gap. The aid amount can in no case exceed the eligible costs established in Step 1.*

*b) In case of a counterfactual alternative project:*

*• Where there is a counterfactual alternative project, there is a counterfactual tab in the Excel sheet with full calculation of the net present value of the positive and negative cash flows of the counterfactual project.*

*• Proportionality of aid amount per beneficiary company in the IPCEI Communication in case there is an alternative project:*

*Step 1) Identify the eligible costs in the basic scenario: The possible eligible costs are listed in the Annex of the IPCEI Communication. The aid amount for any beneficiary can in no case exceed*

*100% of the eligible costs;*

*Step 2) Identify the difference between the NPV of the alternative project and the NPV of the aided project in the basic scenario.*

*In general, the aid amount corresponds to this difference. In the Excel sheet, it would be convenient to insert this calculation at the bottom of the basic scenario tab.*

*The aid amount can in no case exceed the eligible costs established in step 1.*

1. Elaboration on Terms of the Funding Gap Questionnaire

*Each company should provide all costs and revenues associated with the investment as a whole and the boundaries of investment should be defined from the perspective of the business investor: the calculation should include all (positive and negative) cash-flows for what the investor regards as the investment project, at the time these cash-flows are to be incurred. It is not enough to only submit the eligible costs. For the purpose of calculating the funding gap, what matters are all the costs (eligible or not) associated with the investment project and all the revenues over the entire lifetime including the mass production phase.*

*• The funding gap calculation is to be done consistent with the following methodology:*

*• For the purposes of this IPCEI, it is sufficient to provide the Excel sheet calculations for one scenario, the basic scenario (no optimistic and pessimistic scenarios and respective probabilities needed), provided the company is able to justify in the accompanying text document why this basic scenario is the most probable one.*

*• The funding gap that must be calculated is the funding gap of the investment project (i.e. all investment costs and operating costs) to be made by the company for the purpose of the IPCEI.*

*• The investments made for the IPCEI in R&D and FID by a company will generate revenues.*

*• The funding gap is the difference between discounted positive and negative cash flows over the entire economic lifetime of the investment project, i.e. covering the entire period during which the investments made generate revenues / the products that are produced thanks to programme. The investments are sold on the market. Hence, the funding gap must not be calculated only for the duration of the IPCEI project, which is up to the end of the FID phase, but must also cover the ensuing commercial/mass production phase.*

*• One option is to include in the excel sheet the best estimate projections that the company has for this entire period.*

*• Alternatively, companies could provide data for the explicit forecast horizon of the company and give a residual/terminal value (i.e. net present value of expected cash flow beyond the explicit forecast horizon for the remaining years of the economic lifetime), discounted to the current value. In that case, the number of years of mass production for which data are inserted should be realistic.*

*• Practically, in the Excel sheet, after the data for the FID phase and after the data for the reasonable number of years of mass production, a column should be inserted and contain the terminal value for the costs and for the revenues.*

*• Sales/revenues (positive cash flows): projected sales figures should be used by each company rather than a formula. These should be the figures actually used by the company in its business plan and decision making process. This can be best estimate figures. This data should overwrite the formula embedded in the Excel sheet which calculates sales/revenues as a function of costs, an assumption of idle share and an assumption of gross margin. Only if a company has no sales projections or any best estimate data, and only if it actually uses the formula embedded in the sheet (function of costs, idle share and gross margin) in its business plan and decision making process, should it apply the formula.*

*• Cash flows should normally be discounted using the weighted average cost of capital (WACC) of the company. The firm should provide evidence that the discount factor applied is the actual WACC used by the company (e.g. by internal documents showing the applied WACC for investment analysis). The reason to deviate from the WACC usually applied by the company should be explained in detail.*

*• The end result of this step should be one figure: the amount of the funding gap, labelled as such in the Excel sheet.*

* 1. Incentive effect
		1. Start date of the project

*The project didn’t have to start before the reception of the submission by the member state*

* + 1. Increase in R&D and FID efforts
		2. Risks affecting the project
	1. Necessity of state aid

*Point 28 of the guidelines.*

*The aid must not subsidise the costs of a project that an undertaking would anyhow incur andmust not compensate for the normal business risk of an economic activity. Without the aid the project’s realisation should be impossible, or it should be realised in a smaller size or scope or in a different manner that would significantly restrict its expected benefits. Aid will only be consideredproportionate if the same result could not be achieved with less aid.*

* 1. Proportionality of state aid

*Point 30 of the guidelines.*

*The funding gap and proportionality of aid will be assessed at the level of each clearly identifiable underlying individual component / single project.*

*The Proportionality of aid amount per beneficiary company in the IPCEI Communication is assessed by:1) Identifying the eligible costs: The possible eligible costs are listed in the Annex of the IPCEICommunication. The aid amount for any beneficiary can in no case exceed 100% of theeligible costs;2) Identifying the funding gap. The aid cannot be higher than the funding gap (and, at the sametime cannot be more than 100% of eligible costs).The maximum aid amount corresponds to the funding gap, provided it does not exceed theeligible costs established in Step 1.*

* + 1. Costs and state aid
		2. State aid cumulation
		3. Open selection proceeding

*Explain whereas the State aid* (*expressed in gross grant equivalent for non-transparent aid) is not exceeding the funding gap*

1. Limitation of distortion of competition and trade

*IPCEIs make it possible to bring together knowledge, expertise, financial resources and economicactors throughout the Union, so as to overcome important market or systemic failures and societal challenges which could not otherwise be addressed.*

*Please describe in this chapter in a detailed and comprehensive way why the IPCEI funding of your project will not lead to market, trade or competition distortion (or does so only to a very limited extent) and why in this context the development of your technology is necessary in Europe.*

* 1. Market affected by the state aid
		1. Current Industry Sector

*Description of the market situation (EU and worldwide) in this sector (market share, competitors).*

* + 1. Market Situation / Share after IPCEI

*Estimation of the market situation / share (EU and worldwide) after the project will have been finished successfully.*

* 1. Limiting distortion of dynamic incentives

*Please describe why the IPCEI funding will not deter your competitors’ investments in R&D and FID to develop competing technologies.* *No strengthening or creation of market power*

*Please explain why the IPCEI funding will not lead your company to market power (market leadership)*

* 1. No strengthening or creation of market power
	2. Failure to maintain an inefficient market structure

*Please describe why the technology you are addressing is not located in an “inefficient” market suffering from for example overcapacity nor a declining sector*

* 1. No effect on location activities

*Please describe that knowledge/technology that will be generated within the IPCEI will not be transferred to non-European locations of your company.*

*Please describe that there will be no subsidy race within Europe.*

1. Annex to the Portfolio
2. *Funding Gap Questionnaire*
3. *(If necessary) Internal Company Documents substantiating the counterfactual scenario*
1. Reference to (g) in the annex of the ICPEI communication from the Commission (2021/C(2021) 8481 final) [↑](#footnote-ref-1)